EICHORCondition: Advanced Metastatic Castration-resistant Prostate Cancer · Prostate Specific Membrane Antigen (PSMA) Expression · Sponsor: Bayer
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prostate (male reproductive gland found below the bladder) that has spread to other parts of the body. This type of prostate cancer does not respond to hormone treatment used to lower the level of testosterone, a male sex hormone, to prevent cancer from growing. The study treatment 225Ac-PSMA-Trillium, also called BAY3563254, is under development to treat advanced metastatic castration-resistant prostate cancer. It works by binding to PSMA and giving off radiation that can damage cancer cells and stop them from growing. The main purpose of this first-in-human study is to learn: * How safe is BAY3563254 in participants. * What is the recommended dose of BAY3563254 that is safe and works well that will be further tested in Part 2 of the study. * How well does BAY3563254 work in participants. To answer this, the researchers will look at: * The number and severity of medical problems including serious medical problems that participants experience after taking BAY3563254 * The number of dose-limiting toxicities (DLT) at each dose level. A DLT is a medical problem caused by a drug that is too severe to continue the use of that specific dose. * The number of participants whose cancer completely disappears (complete response) or reduces by at least 30% (partial response) after taking the treatment (also known as objective resp…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| City of Hope - Duarte Cancer Center | Duarte, California, United States | Not Yet Recruiting |
| M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center | Minneapolis, Minnesota, United States | Not Yet Recruiting |
| XCancer Omaha | Omaha, Nebraska, United States | Not Yet Recruiting |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston, Texas, United States | Not Yet Recruiting |
| Institut Jules Bordet / Nuclear Medicine | Anderlecht, Brussels Capital, Belgium | Recruiting |
| UZ Leuven - Campus Gasthuisberg - Nuclear Medicine | Leuven, Flemish Brabant, Belgium | Not Yet Recruiting |
| AZ Groeninge Campus Kennedylaan - Urology | Kortrijk, West Flanders, Belgium | Recruiting |
| Cross Cancer Institute | Clinical Trials Unit | Edmonton, Alberta, Canada | Withdrawn |
| BC Cancer | Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| Juravinski Cancer Centre | Clinical Trials | Hamilton, Ontario, Canada | Recruiting |
| Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology | Toronto, Ontario, Canada | Recruiting |
| Centre Hospitalier de l'Universite de Montreal (CHUM) | Oncology | Montreal, Quebec, Canada | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06217822